@inbook{6148ce60d7aa49b98f53066e931ee413,
title = "Waldenstrom macroglobulinemia: Genomic aberrations and treatment",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.",
keywords = "BTK inhibitors, CXCR4, IgM, MYD88, Waldenstrom{\textquoteright}s macroglobulinemia",
author = "Prashant Kapoor and Ansell, {Stephen M.} and Esteban Braggio",
note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",
year = "2016",
doi = "10.1007/978-3-319-40320-5_16",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "321--361",
booktitle = "Cancer Treatment and Research",
address = "Netherlands",
}